

# Jeffrey L Bennett

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3997899/publications.pdf>

Version: 2024-02-01

79  
papers

8,941  
citations

57719

44  
h-index

66879

78  
g-index

81  
all docs

81  
docs citations

81  
times ranked

6284  
citing authors

#	ARTICLE	IF	CITATIONS
1	The changing landscape of optic neuritis: a narrative review. <i>Journal of Neurology</i> , 2022, 269, 111-124.	1.8	28
2	AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 57, 103356.	0.9	16
3	A new form of axonal pathology in a spinal model of neuromyelitis optica. <i>Brain</i> , 2022, 145, 1726-1742.	3.7	10
4	Evaluation of Plasma Neurofilament Light Chain Levels as a Biomarker of Neuronal Injury in the Active and Chronic Phases of Autoimmune Neurologic Disorders. <i>Frontiers in Neurology</i> , 2022, 13, 689975.	1.1	6
5	Association of Maintenance Intravenous Immunoglobulin With Prevention of Relapse in Adult Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. <i>JAMA Neurology</i> , 2022, 79, 518.	4.5	39
6	In utero exposure to maternal anti-aquaporin-4 antibodies alters brain vasculature and neural dynamics in male mouse offspring. <i>Science Translational Medicine</i> , 2022, 14, eabe9726.	5.8	11
7	Heterogeneity of Acetylcholine Receptor Autoantibody-Mediated Complement Activity in Patients With Myasthenia Gravis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	3.1	21
8	Differential Effects of Fingolimod and Natalizumab on B Cell Repertoires in Multiple Sclerosis Patients. <i>Neurotherapeutics</i> , 2021, 18, 364-377.	2.1	20
9	Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD. <i>Multiple Sclerosis Journal</i> , 2021, 27, 2052-2061.	1.4	11
10	Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	20
11	Blood-brain barrier resealing in neuromyelitis optica occurs independently of astrocyte regeneration. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	18
12	Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker. <i>Annals of Neurology</i> , 2021, 89, 895-910.	2.8	72
13	Age-dependent favorable visual recovery despite significant retinal atrophy in pediatric MOGAD: how much retina do you really need to see well?. <i>Journal of Neuroinflammation</i> , 2021, 18, 121.	3.1	22
14	A Longitudinal, Observational Analysis of Neuronal Injury Biomarkers in a Case Report of a Patient With Paraneoplastic Anti-CRMP5 Antibody-Associated Transverse Myelitis. <i>Frontiers in Neurology</i> , 2021, 12, 691509.	1.1	4
15	Clinical Features and Outcomes of Pediatric Monophasic and Recurrent Idiopathic Optic Neuritis. <i>Journal of Child Neurology</i> , 2020, 35, 77-83.	0.7	5
16	Affinity-matured aquaporin-4 antibody for therapy of seropositive neuromyelitis optica spectrum disorders. <i>Neuropharmacology</i> , 2020, 162, 107827.	2.0	32
17	Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	112
18	Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 44, 102251.	0.9	110

#	ARTICLE	IF	CITATIONS
19	Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. <i>Neurology</i> , 2020, 95, e111-e120.	1.5	140
20	Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. <i>Lancet Neurology</i> , The, 2020, 19, 402-412.	4.9	278
21	Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial. <i>Lancet Neurology</i> , The, 2020, 19, 391-401.	4.9	183
22	Induction of aquaporin 4-reactive antibodies in Lewis rats immunized with aquaporin 4 mimotopes. <i>Acta Neuropathologica Communications</i> , 2020, 8, 49.	2.4	5
23	Novel clinical features of glycine receptor antibody syndrome. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e592.	3.1	43
24	Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOMentum): a double-blind, randomised placebo-controlled phase 2/3 trial. <i>Lancet</i> , The, 2019, 394, 1352-1363.	6.3	433
25	Early B cell tolerance defects in neuromyelitis optica favour anti-AQP4 autoantibody production. <i>Brain</i> , 2019, 142, 1598-1615.	3.7	62
26	Concentration-dependent effects of CSF1R inhibitors on oligodendrocyte progenitor cells ex vivo and in vivo. <i>Experimental Neurology</i> , 2019, 318, 32-41.	2.0	53
27	Membrane assembly of aquaporin-4 autoantibodies regulates classical complement activation in neuromyelitis optica. <i>Journal of Clinical Investigation</i> , 2019, 129, 2000-2013.	3.9	81
28	Distinct patterns of glia repair and remyelination in antibody-mediated demyelination models of multiple sclerosis and neuromyelitis optica. <i>Glia</i> , 2018, 66, 2575-2588.	2.5	23
29	Mutations of Recombinant Aquaporin-4 Antibody in the Fc Domain Can Impair Complement-Dependent Cellular Cytotoxicity and Transplacental Transport. <i>Frontiers in Immunology</i> , 2018, 9, 1599.	2.2	4
30	Comparative molecular dynamics study of neuromyelitis optica-immunoglobulin G binding to aquaporin-4 extracellular domains. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2017, 1859, 1326-1334.	1.4	9
31	Determining the Spatial Relationship of Membrane-Bound Aquaporin-4 Autoantibodies by STED Nanoscopy. <i>Biophysical Journal</i> , 2017, 112, 1692-1702.	0.2	4
32	CNS Aquaporin-specific B cells connect with multiple cell compartments in neuromyelitis optica spectrum disorder. <i>Annals of Clinical and Translational Neurology</i> , 2017, 4, 369-380.	1.7	53
33	Dural sinus stenting for idiopathic intracranial hypertension: factors associated with hemodynamic failure and management with extended stenting. <i>Journal of NeuroInterventional Surgery</i> , 2017, 9, 867-874.	2.0	41
34	Glucose-regulated protein 78 autoantibody associates with blood-brain barrier disruption in neuromyelitis optica. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	110
35	Efficacy of Polyvalent Human Immunoglobulins in an Animal Model of Neuromyelitis Optica Evoked by Intrathecal Anti-Aquaporin 4 Antibodies. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1407.	1.8	10
36	Tolerance checkpoint bypass permits emergence of pathogenic T cells to neuromyelitis optica autoantigen aquaporin-4. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 14781-14786.	3.3	59

#	ARTICLE	IF	CITATIONS
37	Variable sensitivity to complement-dependent cytotoxicity in murine models of neuromyelitis optica. <i>Journal of Neuroinflammation</i> , 2016, 13, 301.	3.1	12
38	Finding NMO: The Evolving Diagnostic Criteria of Neuromyelitis Optica. <i>Journal of Neuro-Ophthalmology</i> , 2016, 36, 238-245.	0.4	23
39	Placebo-controlled study in neuromyelitis optica—Ethical and design considerations. <i>Multiple Sclerosis Journal</i> , 2016, 22, 862-872.	1.4	63
40	Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD. <i>Science China Life Sciences</i> , 2016, 59, 1270-1281.	2.3	47
41	The Ins and Outs of B Cells in Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2015, 6, 565.	2.2	54
42	Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum Disorder. <i>JAMA Neurology</i> , 2015, 72, 815.	4.5	59
43	The intrinsic pathogenic role of autoantibodies to aquaporin 4 mediating spinal cord disease in a rat passive-transfer model. <i>Experimental Neurology</i> , 2015, 265, 8-21.	2.0	59
44	Re-evaluating the treatment of acute optic neuritis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 799-808.	0.9	29
45	Varicella Zoster Virus in Ischemic Optic Neuropathy. <i>Ophthalmology</i> , 2015, 122, 2142-2145.	2.5	9
46	International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. <i>Neurology</i> , 2015, 85, 177-189.	1.5	3,275
47	ATON: Results from a Phase II randomized trial of the B-cell-targeting agent atacicept in patients with optic neuritis. <i>Journal of the Neurological Sciences</i> , 2015, 351, 174-178.	0.3	71
48	Prevalence and distribution of VZV in temporal arteries of patients with giant cell arteritis. <i>Neurology</i> , 2015, 84, 1948-1955.	1.5	156
49	The cerebrospinal fluid immunoglobulin transcriptome and proteome in neuromyelitis optica reveals central nervous system-specific B cell populations. <i>Journal of Neuroinflammation</i> , 2015, 12, 19.	3.1	48
50	Mutagenesis of the Aquaporin 4 Extracellular Domains Defines Restricted Binding Patterns of Pathogenic Neuromyelitis Optica IgG. <i>Journal of Biological Chemistry</i> , 2015, 290, 12123-12134.	1.6	33
51	Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid cause demyelination of spinal cord explants. <i>Acta Neuropathologica</i> , 2015, 130, 765-781.	3.9	76
52	B lymphocytes in neuromyelitis optica. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e104.	3.1	132
53	Update on biomarkers in neuromyelitis optica. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e134.	3.1	104
54	Analysis of Varicella-Zoster Virus in Temporal Arteries Biopsy Positive and Negative for Giant Cell Arteritis. <i>JAMA Neurology</i> , 2015, 72, 1281.	4.5	101

#	ARTICLE	IF	CITATIONS
55	Evaluation of aquaporin-4 antibody assays. <i>Clinical and Experimental Neuroimmunology</i> , 2014, 5, 290-303.	0.5	106
56	Early loss of oligodendrocytes in human and experimental neuromyelitis optica lesions. <i>Acta Neuropathologica</i> , 2014, 127, 523-538.	3.9	38
57	Experimental mouse model of optic neuritis with inflammatory demyelination produced by passive transfer of neuromyelitis optica-immunoglobulin G. <i>Journal of Neuroinflammation</i> , 2014, 11, 16.	3.1	53
58	Treatment of neuromyelitis optica: state-of-the-art and emerging therapies. <i>Nature Reviews Neurology</i> , 2014, 10, 493-506.	4.9	220
59	Involvement of antibody-dependent cell-mediated cytotoxicity in inflammatory demyelination in a mouse model of neuromyelitis optica. <i>Acta Neuropathologica</i> , 2013, 126, 699-709.	3.9	95
60	Neuromyelitis Optica IgG Causes Placental Inflammation and Fetal Death. <i>Journal of Immunology</i> , 2013, 191, 2999-3005.	0.4	90
61	Neuromyelitis optica IgG does not alter aquaporin-4 water permeability, plasma membrane M1/M23 isoform content, or supramolecular assembly. <i>Glia</i> , 2012, 60, 2027-2039.	2.5	47
62	Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica. <i>Annals of Neurology</i> , 2012, 71, 314-322.	2.8	232
63	Intravenous Neuromyelitis Optica Autoantibody in Mice Targets Aquaporin-4 in Peripheral Organs and Area Postrema. <i>PLoS ONE</i> , 2011, 6, e27412.	1.1	73
64	Ex vivo spinal cord slice model of neuromyelitis optica reveals novel immunopathogenic mechanisms. <i>Annals of Neurology</i> , 2011, 70, 943-954.	2.8	142
65	Binding Affinity and Specificity of Neuromyelitis Optica Autoantibodies to Aquaporin-4 M1/M23 Isoforms and Orthogonal Arrays. <i>Journal of Biological Chemistry</i> , 2011, 286, 16516-16524.	1.6	161
66	Viruses and Multiple Sclerosis. <i>Neuroscientist</i> , 2011, 17, 659-676.	2.6	60
67	Evidence against Cellular Internalization in Vivo of NMO-IgG, Aquaporin-4, and Excitatory Amino Acid Transporter 2 in Neuromyelitis Optica. <i>Journal of Biological Chemistry</i> , 2011, 286, 45156-45164.	1.6	60
68	Konsensusprotokoll zur Standardisierung von Entnahme und Biobanking des Liquor cerebrospinalis / A consensus protocol for the standardisation of cerebrospinal fluid collection and biobanking. <i>Laboratoriums Medizin</i> , 2010, 34, 1-12.	0.1	3
69	Live Cell Analysis of Aquaporin-4 M1/M23 Interactions and Regulated Orthogonal Array Assembly in Glial Cells. <i>Journal of Biological Chemistry</i> , 2009, 284, 35850-35860.	1.6	77
70	Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid. <i>Annals of Neurology</i> , 2009, 65, 639-649.	2.8	176
71	Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. <i>Annals of Neurology</i> , 2009, 66, 617-629.	2.8	516
72	Update on Inflammation, Neurodegeneration, and Immunoregulation in Multiple Sclerosis. <i>Clinical Neuropharmacology</i> , 2009, 32, 121-132.	0.2	82

#	ARTICLE	IF	CITATIONS
73	CSF IgG heavy-chain bias in patients at the time of a clinically isolated syndrome. Journal of Neuroimmunology, 2008, 199, 126-132.	1.1	32
74	VH4 Gene Segments Dominate the Intrathecal Humoral Immune Response in Multiple Sclerosis. Journal of Immunology, 2007, 179, 6343-6351.	0.4	68
75	Natalizumab and progressive multifocal leukoencephalopathy: migrating towards safe adhesion molecule therapy in multiple sclerosis. Neurological Research, 2006, 28, 291-298.	0.6	27
76	Screening Random Peptide Libraries with Subacute Sclerosing Panencephalitis Brain-Derived Recombinant Antibodies Identifies Multiple Epitopes in the C-Terminal Region of the Measles Virus Nucleocapsid Protein. Journal of Virology, 2006, 80, 12121-12130.	1.5	17
77	Developmental Neurogenetics and Neuro-Ophthalmology. Journal of Neuro-Ophthalmology, 2002, 22, 286-296.	0.4	11
78	Epstein-barr virus-associated acute autonomic neuropathy. Annals of Neurology, 1996, 40, 453-455.	2.8	55
79	Sustained long-term efficacy and safety of satralizumab in NMOSD. , 0, , .		0